Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) issued its earnings results on Monday. The company reported ($2.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.64) by $0.20, FiscalAI reports. The firm had revenue of $13.54 million for the quarter, compared to analysts’ expectations of $7.72 million. Tonix Pharmaceuticals had a negative net margin of 839.52% and a negative return on equity of 67.65%.
Here are the key takeaways from Tonix Pharmaceuticals’ conference call:
- TONMYA sales accelerated: Second-quarter net sales reached approximately $11 million, up 197% quarter over quarter, while prescriptions, new patient starts, and refills all increased. Management attributed the momentum to positive prescriber feedback, tolerability, and strong refill activity.
- Market access and commercial expansion are progressing: TONMYA coverage currently reaches about 136 million U.S. lives, with coverage expected to rise to approximately 145 million on January 1, 2027. Tonix is adding 50 sales representatives, bringing the field force to roughly 150 by September, to support broader geographic and prescriber coverage.
- Gross-to-net remains variable: Favorable retail and specialty distribution mix and lower copay assistance costs supported second-quarter results, but management expects continued quarterly fluctuations as new payer agreements generate downstream effects. Wholesaler inventory days remained consistent, with no reported incremental inventory buildup.
- Pipeline programs advanced: Tonix randomized the first patient in the phase II HORIZON study of TNX-102 SL for major depressive disorder and expects to begin enrollment of an adaptive phase II study of TNX-4800 for Lyme disease prevention in the first quarter of 2027. Management believes the Lyme study could potentially provide pivotal efficacy evidence if enough infections occur in the placebo group.
- Operating expenses and funding needs increased: Second-quarter R&D expense rose to approximately $19.4 million and SG&A to $36 million, largely due to clinical development and TONMYA commercial investments. Cash and equivalents declined to $176.2 million at quarter-end, with current resources and subsequent equity proceeds expected to fund operations into early second quarter 2027.
Tonix Pharmaceuticals Price Performance
Shares of TNXP stock opened at $12.59 on Tuesday. The stock’s fifty day simple moving average is $11.62 and its 200 day simple moving average is $13.43. Tonix Pharmaceuticals has a one year low of $9.40 and a one year high of $69.97. The firm has a market cap of $200.68 million, a price-to-earnings ratio of -0.88 and a beta of 1.69.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on TNXP
Insider Activity
In other Tonix Pharmaceuticals news, CEO Seth Lederman acquired 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The shares were acquired at an average price of $11.79 per share, with a total value of $58,950.00. Following the purchase, the chief executive officer owned 9,005 shares of the company’s stock, valued at $106,168.95. This represents a 124.84% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Richard Newcomb Stillwell purchased 5,000 shares of the stock in a transaction on Monday, June 8th. The stock was acquired at an average price of $11.65 per share, with a total value of $58,250.00. Following the completion of the acquisition, the director directly owned 5,000 shares of the company’s stock, valued at approximately $58,250. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 11,415 shares of company stock valued at $132,128 in the last 90 days. Corporate insiders own 2.00% of the company’s stock.
Institutional Trading of Tonix Pharmaceuticals
Hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc bought a new stake in Tonix Pharmaceuticals in the 2nd quarter valued at $25,000. State of Wyoming bought a new stake in Tonix Pharmaceuticals during the 4th quarter worth about $27,000. Russell Investments Group Ltd. bought a new stake in Tonix Pharmaceuticals during the third quarter worth about $29,000. BNP Paribas Financial Markets bought a new position in Tonix Pharmaceuticals in the second quarter valued at approximately $65,000. Finally, New York State Common Retirement Fund bought a new position in Tonix Pharmaceuticals in the second quarter valued at approximately $104,000. 82.26% of the stock is currently owned by institutional investors and hedge funds.
Tonix Pharmaceuticals News Summary
Here are the key news stories impacting Tonix Pharmaceuticals this week:
- Positive Sentiment: TONMYA sales surged: Second-quarter net product revenue reached $13.5 million, up from $2.0 million a year earlier. TONMYA sales were approximately $11.0 million, representing 197% sequential growth, while prescriptions doubled to 12,592. Coverage expanded to about 136 million lives, or 43% of U.S. covered lives. Tonix Pharmaceuticals Reports Q2 Revenue of $13.5 Million
- Positive Sentiment: Quarterly results exceeded expectations: Tonix reported adjusted? No—reported EPS of negative $2.44, better than the consensus estimate of negative $2.64, while revenue of $13.54 million exceeded the $7.72 million forecast. The company is expanding its commercial organization with 50 additional representatives, targeting a sales force of approximately 150 by September. Tonix Second-Quarter Financial Results
- Positive Sentiment: Pipeline progress added support: Tonix enrolled the first patient in the Phase 2 HORIZON study of TNX-102 SL for major depressive disorder. Management also outlined plans for a Phase 2 adaptive study of TNX-4800 in Lyme disease prevention, expected to begin in the first quarter of 2027 subject to final FDA review. Tonix Outlines TNX-4800 Phase II
- Neutral Sentiment: Funding runway: Tonix reported approximately $176.2 million in cash and cash equivalents at June 30 and said cash plus proceeds from equity offerings to date should fund planned expenditures into early second-quarter 2027. Additional financing could nevertheless create dilution for shareholders. Tonix Q2 2026 Earnings Call Transcript
- Negative Sentiment: Profitability remains weak: Tonix posted a $40.6 million net loss, or negative $2.44 per share, with a negative net margin of approximately 840%. The company remains dependent on continued TONMYA growth and successful clinical development to support its valuation.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.
Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.
Featured Articles
- Five stocks we like better than Tonix Pharmaceuticals
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
